Improved Prognostic Testing for Patients with Triple Negative Breast Cancer

Update Item Information
Title Improved Prognostic Testing for Patients with Triple Negative Breast Cancer
Creator Varley, K.E.
Subject Diffusion of Innovation; Triple Negative Breast Neoplasms; Prognosis; Kaplan-Meier Estimate; Biomarkers; Enzyme-Linked Immunosorbent Assay; Sensitivity and Specificity; Precision Medicine; Disease-Free Survival; Knowledge Discovery
Keyword Cancer
Image Caption Kaplan-Meier curve that stratifies patients in the training set based on the Immune Activation Score threshold that provides 95% specificity.
Description Approximately 40% of patients with stage I-III triple-negative breast cancer (TNBC) have recurrences after standard treatment, whereas the remaining 60% experience long-term disease-free survival. However, there are currently no clinical tests to assess the risk of recurrence in TNBC patients. To address this issue, Varley and colleagues developed a multigene MHCII Immune Activation Assay to allow clinical testing for the prognosis of recurrence of triple-negative breast cancer patients. This assay identifies TNBC patients with a low risk of recurrence whose tumors express factors like MHC II pathway components, which promote immune infiltration and responses that reduce relapse and enhance survival. This work addressed a critical need for prognostic biomarker tests that enable precision medicine for TNBC patients.
Relation is Part of 2019
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date Digital 2020
Date 2019
Type Image
Format image/jpeg
Rights Management Copyright © 2021, University of Utah, All Rights Reserved
Language eng
ARK ark:/87278/s62v8553
References 1.) Expression of the MHC class II pathway in triple-negative breast cancer tumor cells is associated with a good prognosis and infiltrating lymphocytes. Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE. Cancer Immunol Res. 2016 May;4(5):390. https://pubmed.ncbi.nlm.nih.gov/26980599/ 2.) A multigene assay determines risk of recurrence in patients with triple-negative breast cancer. Stewart RL, Updike KL, Factor RE, Henry NL, Boucher KM, Bernard PS, Varley KE. Cancer Res. 2019 Jul;79(13):3466. https://pubmed.ncbi.nlm.nih.gov/31048497/
Press Releases and Media Determining Risk of Recurrence in Triple-Negative Breast Cancer https://healthcare.utah.edu/huntsmancancerinstitute/news/2019/06/determining-risk-of-recurrence-in-triple-negative-breast-cancer.php
Setname ehsl_50disc
ID 1589362
Reference URL https://collections.lib.utah.edu/ark:/87278/s62v8553
Back to Search Results